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Gliomas are one of the most common primary brain tumors and the etiology 
of gliomas remains unknown in most cases. The aim of this case–control study 
was to investigate possible association between incidence in relation to glioma and 
certain blood groups. This study included 100 histopathologically verified cases of 
glioma and 200 age and sex-matched controls without malignant diseases that were 
admitted to the same hospital. The results revealed that the patients with group AB 
were at 3.5-fold increased risk of developing glioma compared to the patients with 
other ABO blood groups. In this particular study, there was more male patients 
with glioma with the blood group AB. However, mechanisms that explain the 
relationship between the blood groups ABO and a cancer risk are unclear. Several 
hypotheses have been proposed, including the one with a modulatory role of blood 
group ABO antigens. In addition, the blood group ABO system regulates the level of 
circulating proinflammatory and adhesion molecules which play a significant role in 
the tumorigenesis process. Additionally, the recent discovery that includes the von 
Willebrand factor (vWF) as an important modulator of angiogenesis and apoptosis 
provides one plausible explanation as regards the role of the blood group ABO in the 
tumorigenesis process. To our knowledge, this is the first study that examined the 
relationship of blood group in patients diagnosed with glioma among the Serbian 
population. Moreover, for the first time our study results suggested that blood 
group AB increased the risk of glioma. The results of this study suggested that the 
blood group AB could be one of hereditary factors which had an influence on the 
occurrence of glioma. The further research is needed on a larger sample, to confirm 
these findings and the possible mechanisms by which the ABO system contributes 
to the pathology of glioma.
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1. Introduction
The three most prevalent primary tumors of the brain, which represent the most 
common neoplasm of all brain tumors, are glioma, meningioma and pituitary ade-
noma. The most common primary brain tumors are gliomas [1]. Gliomas account 
for 27% of all central nervous system tumors and about 80% of malignant brain 
tumors. Based on the histological criteria, gliomas are classified into the following 
subtypes: astrocytoma, glioblastoma, oligodendroglioma, ependymoma, mixed 
glioma, malignant glioma, not otherwise specified (NOS) and a few rare histologies 
[2]. Each year, approximately 100,000 people are diagnosed with glioma world-
wide. In addition, gliomas comprise less than 2% of all newly diagnosed cancers 
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and are associated with substantial mortality and morbidity [3]. Glioblastoma 
multiforme (GBM) is the highest grade glioma (grade IV) tumor according to 
the grading system of the World Health Organization (WHO classification), and 
accounts for more than 50% of all gliomas [4]. The median overall survival of 
patients with glioma is approximately 14-17 months, whereas the incidence of 
gliomas is 6.8/100,000 and it is increasing worldwide. The countries with Northern 
European populations had higher incidence rates (ranging from 7.8 in the USA to 
9.6 in Australia and New Zealand). However, a decline in the incidence rates was 
noticed in countries with predominantly Asian and Africans populations (ranging 
from 1.9 in Southeast Asia to 3.3 in India) [5]. Considering the fact that the etiol-
ogy of glioma is largely unknown, numerous risk factors have been examined as 
potential contributors to glioma risk. As a result, several potential factors are found 
to be increasing the risk of developing glioma and they included environmental 
factors such as smoking, alcohol consumption, diet, obesity, infections, environ-
mental pollution, and ionizing radiation [6, 7]. In this regard, some epidemiologi-
cal studies suggested that allergic conditions (such as asthma, hay fever, eczema, 
food allergies, etc.) reduced the risk of glioma [8]. Well-established risk factors 
for glioma development include older age, male gender, Caucasian race/ethnicity, 
complete with rare genetic syndromes. Li-Fraumeni syndrome, neurofibromatosis 
(types 1 and 2), tuberous sclerosis, nevoid basal cell carcinoma syndrome, familial 
adenomatous polyposis (FAP), and von Hippel–Lindau (VHL) syndrome cause a 
small percentage of gliomas in adult populations [9–11]. In addition, ABO blood 
groups, expressed by different cells in human tissues, including epithelial cells, 
vascular endothelial cells, and neurons [12], have been associated with an increased 
cancer risk.
Many recent studies have focused on the role of ABO blood group antigens in 
the pathogenesis of various systemic diseases, including cancer. Recently, more 
evidence suggested that there was a significant association between the distribu-
tion of ABO blood group antigens and a risk of tumors, including the development 
of pancreatic cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, and 
gastric cancer [13–15].
Furthermore, several studies have shown conflicting results concerning the 
relationship between ABO blood groups and glioma risk [16–29]. Finally, differ-
ences are observed not only in the distribution of ABO blood group antigens among 
patients with primary brain tumors in various countries worldwide, but also among 
different ethnic groups within the country. The influence of blood group types on 
the pathogenesis of brain tumors is still unclear, considering the fact that there are 
conflicting reports obtained from the studies related to the distribution of ABO 
blood groups and a risk of developing glioma.
2. The relationship between ABO blood group and cancer risk
The ABO blood group system was discovered at the University of Vienna in 
1901 by Austrian scientist, Karl Landsteiner. The locus for the ABO blood group is 
on chromosome 9, whereas ABO gene is inherited in an autosomal dominant [30]. 
The A and B antigens are displayed on the surface membrane of red blood cells and 
attached to a common precursor of the side chain, the H determinant, which is then 
converted into the A or B antigen. As regards the expression of antigens, individuals 
with blood type AB have both antigens (A, B). On the other hand, individuals with 
blood type A have antigen A, individuals with blood type B have antigen B, whereas 
individuals with blood type O have neither antigen A, nor antigen B. Moreover, the 
individuals of group O lack such functional enzymes and express the unaltered H 
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determinants. In addition to their expression on the erythrocytes, A and B antigens 
are highly expressed on the surface of epithelial cells of gastrointestinal, broncho-
pulmonary, and urogenital tracts. Ultimately, they are expressed on the surface of 
the neurons, platelets, and vascular endothelium [31, 32].
The possibility of association between ABO blood type and malignancy was 
first explored by Anderson and Haas. ABO blood group antigens are widely 
expressed in a variety of human cells and tissues. As previously mentioned, the 
underlying mechanisms that could explain the direct relationship between the 
ABO blood groups and cancer risk still remains a challenge. One of the probable 
explanations refers to the modulatory role of ABO blood group antigens. In addi-
tion, a variety of tumors show modified expression of ABO antigens on the sur-
face of cancer cells in comparison with normal epithelial cells [32–34]. Moreover, 
what may prevent the immune system from recognizing and destroying tumor 
cells is the structural similarity observed between ABO blood groups antigens and 
tumor antigens. That results in a greater risk of cancer development and progres-
sion [35]. In particular, glycoconjugates are considered to be the key mediators 
of membrane signaling and intracellular adhesion. Hence, they are necessary 
for malignant progression and metastasis [36]. In addition, a link was detected 
between ABO gene polymorphism and proinflammatory and adhesion molecules 
(such as E-selectin, P-selectin, and intracellular adhesion molecule-1) which play 
an important role in tumorigenesis. It is well known that low levels of intercel-
lular adhesion molecule −1 (ICAM-1) facilitate the adhesion of some cancer cells 
to endothelial cells in patients with a non-O blood group. Furthermore, low-level 
ICAM-1 may accelerate cancer progression [37].
Taking into account that the Von Willebrand factor (vWF) plays an indirect 
role in the tumorigenesis process, it has to be emphasized that its main function is 
to initiate platelet adhesion to the endothelial cells upon vascular injury. Being an 
important modulator of angiogenesis and apoptosis, vWF is secreted by vascular 
endothelial cells. The lowest serum levels of these factors have been associated with 
the O blood group, the intermediate levels – with blood groups A and B, whereas 
the highest levels have been associated with blood group AB. In this manner, we did 
observe a positive correlation between levels of vWF and disease severity. The level 
of vWF is an indicator of the extent of endothelial dysfunction caused by tumor 
growth. Thus, elevations in the concentrations of plasma vWF could be related 
to accelerated tumor growth in individuals with non-O blood groups [38, 39]. As 
regards the Forssman antigen (FORS1 Ag), which is structurally similar to the 
structure of A antigen determinant of the ABO blood group system, it is synthesized 
predominantly in stomach and colon cancer. However, one study confirmed the 
presence of Forssman antigen in hepatocellular carcinoma tissues [40]. Alterations 
in surface antigens, particularly glycoconjugates, may not only lead to modifications 
in intercellular adhesion, but could have an important role in the development of 
cancer as well. There is still no formal hypothesis which would provide a plausible 
explanation about the association between malignancy and ABO blood groups [35]. 
Consequently, the ABO gene may be in linkage disequilibrium with other genes 
influencing cancer risk [41].
2.1 The relationship between ABO blood groups and risk of pancreatic cancer
The results obtained from three previously conducted studies indicated a lower 
incidence of pancreatic cancer among people with blood group O. Additionally, 
the Nurses’ Health Study and the Health Professionals Follow-Up Study demon-
strated an increased incidence of pancreatic cancer among subjects with blood 
type antigen A or B compared with those who were lack of these antigens [42–44]. 
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Dandona et al., also observed an increased risk of developing pancreatic cancer in 
patients with a non-O blood group [45].
2.2 The relationship between ABO blood group and risk of gastric cancer
Based on the results of previously conducted study, which included 3,623 
patients from England and Scotland, a significantly higher frequency of the A 
blood group and a lower frequency of the O blood group was observed among 
stomach cancer patients. In addition to the above mentioned findings, it was also 
revealed that the people with blood group B showed a significantly reduced risk 
of stomach cancer [46]. On the other hand, several studies, mostly conducted in 
Western populations, consistently showed an approximately 20% excess risk of 
gastric cancer in individuals with blood type A [47]. The results obtained from this 
particular study confirmed in a recent meta-analysis [48]. Furthermore, there was a 
prospective cohort study in a Taiwanese population that showed the fact that blood 
type A was associated with a 38% increased risk of stomach cancer [49]. In addi-
tion, another prospective cohort study that included middle-aged or older Chinese 
men demonstrated a lower risk of all cancer for blood type B, as well as a lower risk 
for gastrointestinal cancers including stomach and colorectal cancer for blood types 
B and AB rather than blood type A [50]. In a study by Aird et al., no association was 
found between the ABO blood group and risk of stomach cancer [51].
2.3 The relationship between ABO blood groups and lung cancer
The increased risk of developing lung cancer was observed in patients with 
non-O blood type in Turkish populations [52].
2.4 The relationship between ABO blood groups and breast cancer
Having studied the association between ABO blood groups and breast cancer, 
Stamatokos et al., suggested that an A antigen was associated with an increased risk 
of developing breast cancer. In contrast, Tryggvadottir and colleagues observed an 
increased risk among women with B antigen [53, 54]. On the basis of the results of 
a meta-analysis, it was concluded that blood group A was positively linked with an 
increased risk of breast cancer [55].
2.5 The relationship between ABO blood groups and colon cancer
According to the findings of a meta-analysis, which evaluated the association 
between the ABO blood group and colon cancer, the protective effects of O blood 
type were confirmed. However, blood types A and B were not linked to a higher risk 
of colon cancer [56].
2.6 The influence of ABO blood group on the development of glioma
The Central Nervous System (CNS) lesions are known to mankind since 1774. 
Systemic study of the CNS commenced when Baily and Cushing started their 
studies in the early 1920s [57]. The association between brain tumors and blood 
groups antigens is variable. No specific hypothesis has been proposed for the 
association between CNS neoplasms and ABO blood groups. The abovementioned 
mechanisms may operate even in the CNS neoplasms. Kumarguru et al., suggested 
a probable hypothesis which was related to the fact that an alteration in the char-
acteristics of ABO blood group antigens on the surface of cell origin, under the 
5
ABO Blood Groups and Risk of Glioma
DOI: http://dx.doi.org/10.5772/intechopen.100566
influence of either environmental factors or genetic factors, may govern the pro-
cess of development of tumors. In this regard, the mechanism may operate not only 
in the primary neoplastic lesions but in the metastatic lesions of the CNS in the 
genetically susceptible individuals as well [58]. Taking into account that there are 
conflicting reports obtained from studies done on the distribution of ABO blood 
groups in primary intracranial neoplasms, the influence of blood group types on 
the pathogenesis of brain tumors still remains unclear. Periayavan S et al., observed 
that blood group O was common in most of the categories of CNS lesions: neu-
roepithelial tumors (38.45%), meningeal (37.57%), cranial and paraspinal nerve 
tumors (39.67%), pituitary neoplasms (43.62%), and metastatic tumors (43.18%) 
[59]. As regards the study undertaken by Mehrazin M et al., neuroepithelial tumors 
(38.4%), cranial and paraspinal nerve tumors (35.9%), and pituitary neoplasms 
(4.40%) were observed more frequently in O blood group patients in their study 
[59]. In contrast, previous studies showed different results concerning the ratios of 
blood groups among the patients with glioma. Yates and Pearce conducted the first 
study which examined the relationship between the ABO blood group and the risk 
of glioma [16]. In this respect, there was no significant relationship found between 
ABO blood groups and risk of glioma among patients diagnosed before 1945. 
After that year, a highly statistically significant decrease in number of patients 
with blood group O was reported. The relationship between the blood groups and 
astrocytic brain tumors was examined in the study conducted by Selvestrone and 
Cooper [17], the results of which showed a statistically significant decrease in the 
number of patients with blood group B and O. In addition to the abovementioned 
studies, in an Italian case–control study that recruited 195 cases of histologically-
confirmed glioma, a positive association was found with blood group A when low-
grade astrocytomas were considered separately. Additionally, the present study 
identified suggestive, but non-statistically significant association with the presence 
of CNS tumors among the first and second-degree relatives [18]. Compared to the 
general population, Campbell et al., reported a substantially higher incidence of 
glioma in blood group O individuals [19]. Yates et al., did not detect any significant 
differences in the distribution of blood group antigens between glioma patients 
and controls from the Oxford region in the United Kingdom [20]. These results 
were confirmed by Strang et al., in a study that included 900 astrocytoma patients 
and the control population [21]. Furthermore, there was a significantly higher 
number of male cerebral astrocytoma patients with group A confirmed in this 
particular study.
The retrospective study conducted by Mehrazin et al., was made on 907 histo-
logically confirmed cases of glioma and the same number of age and sex-matched 
controls. The distribution of ABO blood groups in this study population was com-
pared with that of the general population. Finally, the results showed no significant 
differences between types of intracranial tumors and frequencies of four blood 
groups [22]. The case–control study by Akhtar et al., on 112 central nervous system 
tumors, found a significantly higher association of these tumors with blood group B 
patients [23]. On the contrary, in a case–control study, Akca et al., aimed to com-
pare the patients with glioblastoma multiforme with control groups regarding ABO 
blood groups. On the basis of the study results, no significant differences among 
O, A, B and AB blood groups were shown [24]. In a study conducted by Turowski 
and Czochra, the analysis was based on the distribution of ABO blood groups in 
271 patients treated for glioblastoma multiforme (GBM), whereas the control group 
included 500 patents with craniocerebral trauma. Hence, a statistically significant 
difference was found in the distribution of ABO blood groups between these patient 
groups. Moreover, higher frequency of group A and lower frequency of group O 
was detected in GMB patients [25]. In the cohort study, Allouh et al., included 
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115 patients who were diagnosed with glioblastoma multiforme (GB) in Jordan, 
between 2004 and 2015. Inclusion criteria were histologically confirmed glioma. 
Due to hospital records, data related to patients’ characteristics (such as the follow-
ing: age, sex, ABO blood groups, and Rh factor) were collected. Consequently, the 
study results suggested that individuals with group A had a higher than expected 
chance of developing glioblastoma multiforme, while individuals with group O 
had a lower chance. In addition, a lower incidence of glioblastoma multiforme 
was reported in individuals with group O compared to healthy blood donors and 
age- and sex-matched control subjects [26]. The case–control study in the Serbian 
population, which consisted of 100 pathohistologically confirmed glioma and 200 
age and sex-matched control individuals, observed a higher incidence of glioma in 
patients with the blood group AB [27].
The aim of the retrospective study done by Chang et al., was to examine the 
relationship between ABO blood groups and brain tumors in the Chinese popula-
tion. This study included 2077 cases with histologically confirmed glioma admitted 
at the hospital in the period between 2001 and 2016, whereas the control group 
included 2716 noncancer patients admitted to the same hospital. Consequently, 
the results showed that blood types B and AB were significantly linked to the 
risk of glioma [28]. In a prospective study, involving more than 100,000 adults 
in the United States and nearly 20 years of follow-up, no statistically significant 
differences in risk of glioma were identified by ABO blood type. Hence, the 
abovementioned study suggested that ABO blood group may not play a role in the 
development of glioma [29].
3. Prognostic value of ABO blood groups in patients with glioma
Some studies investigated the prognostic value of ABO blood groups in patients 
with glioma. Alkan et al., performed a retrospective cross-sectional study which 
included 759 patients with glioma. In this study, there was no statistically significant 
difference observed between glioma patients and healthy control patients. Median 
overall survival (mOS) of GBM patients were 12.9 months in A, 13.4 months in 
B, 5.7 months in AB, 12.8 months in 0 blood groups. The median overall survival 
of anaplastic astrocytoma patients were 24.4 months in A, 47.2 months in B, 
37.8 months in AB, 29.2 months in 0 blood groups respectively. Therefore, these 
results showed that ABO blood groups had no prognostic value [60]. In a retro-
spective study on 72 patients with GMB, Akca et al., found no correlation among 
ABO blood groups and prognosis. In that study, the number of patients with blood 
groups O, A, B, and AB were 23, 33, 9 and 7, respectively [24]. In a retrospective 
observational study, Sokmen et Karcin showed that overall survival was shorter in 
GMB patients with non-O ABO blood groups than those with blood group O. This 
study consisted of 238 patients with GMB and it was the first study showing the 
prognostic value of ABO blood groups in patients with GMB [61]. The reason may 
be that the number of patients was insufficient for prognostic analyses in the study 
conducted by Akca et al.
The previous study, which aimed to evaluate the prognostic value in overall sur-
vival, had some limitations. With this respect, some of the studies failed to obtain 
data regarding O6-methylguanine-DNA methyltransferase (MGMT) promoters, 
which are shown to have prognostic value in GMB. Additionally, some studies 
suggested that overall survival be shorter in GMB patients with non-O ABO blood 
groups than those with blood group O.
It is confirmed that differences in the distribution of ABO among patients 
with primary brain tumors have been reported between countries worldwide, 
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complete with differences between ethnic groups within the country which are 
observed as well.
As regards the effects of ABO blood groups on the incidence and survival of 
patients with glioma, they are still unknown. What can be confirmed is that ABO 
blood status has been shown to be associated with many cancers. However, the 
influence of blood group types on the pathogenesis of glioma is still unclear. Due to 
the difference of ABO genes among socioeconomic groups and geographic areas, the 
blood groups may have a role in the incidence and prognosis of glioma just like the 
environmental factors as well.
4. Conclusion
In conclusion, it should be stated that gliomas are considered to be the most 
common primary brain tumors, accounting for almost 80% of all malignant brain 
tumors. The etiology of glioma is still largely unknown. However, in the past 
decades, a lot of research has been focused on determining risk factors that may 
contribute to glioma aetiopathogenesis, including genetic and environmental 
factors. Previous reports demonstrated that gene mutations and ABO blood groups 
may be associated with elevated glioma risk. Therefore, further research of such 
kind is needed to be performed on a larger sample, for the purpose of confirming 
the abovementioned findings complete with potential mechanisms by which the 
ABO system contributes to the pathology of glioma.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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